An overview of major depression disorder: The endocannabinoid system as a potential target for therapy.

Autor: Zarazúa-Guzmán S; Laboratorio de Neurotoxicología, Facultad de Ciencias Químicas, Universidad Autónoma de San Luis Potosí, San Luis Potosí, Mexico., Vicente-Martínez JG; Facultad de Medicina Veterinaria y Zootecnia, Universidad Veracruzana, Veracruz, Mexico., Pinos-Rodríguez JM; Facultad de Medicina Veterinaria y Zootecnia, Universidad Veracruzana, Veracruz, Mexico., Arevalo-Villalobos JI; Facultad de Medicina Veterinaria y Zootecnia, Universidad Veracruzana, Veracruz, Mexico.
Jazyk: angličtina
Zdroj: Basic & clinical pharmacology & toxicology [Basic Clin Pharmacol Toxicol] 2024 Oct 06. Date of Electronic Publication: 2024 Oct 06.
DOI: 10.1111/bcpt.14089
Abstrakt: Major depressive disorder is the psychiatric disease with the highest global prevalence, impacting social functioning and decreasing the quality of life. The partial pathophysiological knowledge of the disease, the economic burden and the low remission rates are sufficient justification to carry out an update on the subject in the search for new therapeutic approaches and targets. The endocannabinoid system has been linked to the development of depression, and its stimulation or antagonism is a promising approach in the treatment of major depressive disorder. Cannabidiol (CBD) and its properties have been widely studied recently; its analgesic, anti-inflammatory, antineoplastic and neuroprotective roles have even been reported in animal models and clinical trials, achieving its approved use for certain neurodegenerative pathologies. The use of CBD in depression biomodels and clinical trials has not been the exception, and here we contrast the current evidence of its administration and pharmacology against the pathological mechanisms of major depressive disorder.
(© 2024 Nordic Association for the Publication of BCPT (former Nordic Pharmacological Society). Published by John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz: